Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin
Daniel D. Karp, Michael N. Pollak, Roger B. Cohen, Peter D. Eisenberg, Paul Haluska, Donghua Yin, Allan Lipton, Laurence Demers, Kim Leitzel, Mary L. Hixon, Leon W. Terstappen, Linda Garland, Luis G. Paz-Ares, Felipe Cardenal, Corey J. Langer, Antonio Gualberto
Dive into the research topics of 'Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin'. Together they form a unique fingerprint.